Cargando…
Hepatic expression of multidrug resistance protein 2 in biliary atresia
BACKGROUND: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of patients. Postoperative clearance of jaundice is one of the most important fac...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161838/ https://www.ncbi.nlm.nih.gov/pubmed/21813008 http://dx.doi.org/10.1186/1476-5926-10-6 |
_version_ | 1782210738556764160 |
---|---|
author | Terui, Keita Saito, Takeshi Hishiki, Tomoro Sato, Yoshiharu Mitsunaga, Tetsuya Yoshida, Hideo |
author_facet | Terui, Keita Saito, Takeshi Hishiki, Tomoro Sato, Yoshiharu Mitsunaga, Tetsuya Yoshida, Hideo |
author_sort | Terui, Keita |
collection | PubMed |
description | BACKGROUND: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of patients. Postoperative clearance of jaundice is one of the most important factors influencing long-term outcomes of BA patients. Multidrug resistance protein 2 (MRP2) is one of the canalicular export pumps located in hepatocytes; it exports organic anions and their conjugates (e.g., bilirubin) into bile canaliculus. Although MRP2 is an essential transporter for the excretion of bilirubin, its role in the clinical course of BA patients is unclear. The present study investigated the relationship between hepatic MRP2 expression and clinical course in BA patients, with particular emphasis in curing jaundice after hepatoportoenterostomy. RESULTS: No significant differences in hepatic MRP2 expression level were observed between BA and controls groups. There was no correlation between MRP2 expression and age at time of surgery in BA and control groups. In BA patients, MRP2 expression level in the jaundice and jaundice-free group did not differ significantly (2.0 × 10(-4 )vs 3.1 × 10(-4), p = 0.094). Although the serum level of total bilirubin just before surgery did not correlate with MRP2 expression level (rs = 0.031, p = 0.914), the serum level of total bilirubin measured at 2 weeks (rs = -0.569, p = 0.034) and 4 weeks after surgery (rs = -0.620, p = 0.018) were significantly correlated with MRP2 expression level. Furthermore, MRP2 expression level was inversely correlated with ratio of change in serum total bilirubin level over 4 weeks (rs = -0.676, p = 0.008), which represents the serum bilirubin level measured at 4 weeks after surgery divided by value just before surgery. There was no correlation between expression level of MRP2 and nuclear receptors, such as retinoid × receptor α, farnesoid × receptor, pregnane × receptor, or constitutive androstane receptor. CONCLUSIONS: Hepatic MRP2 expression level was associated with postoperative clearance of jaundice in BA patients, at least within 1 month after hepatoportoenterostomy. This finding suggests that not only morphological appearance of the liver tissue but also the biological status of hepatocytes is important for BA pathophysiology. |
format | Online Article Text |
id | pubmed-3161838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31618382011-08-26 Hepatic expression of multidrug resistance protein 2 in biliary atresia Terui, Keita Saito, Takeshi Hishiki, Tomoro Sato, Yoshiharu Mitsunaga, Tetsuya Yoshida, Hideo Comp Hepatol Research BACKGROUND: Biliary atresia (BA) is an idiopathic inflammatory obliterative cholangiopathy of neonates, leading to progressive biliary cirrhosis. Hepatoportoenterostomy (Kasai procedure) can cure jaundice in 30% to 80% of patients. Postoperative clearance of jaundice is one of the most important factors influencing long-term outcomes of BA patients. Multidrug resistance protein 2 (MRP2) is one of the canalicular export pumps located in hepatocytes; it exports organic anions and their conjugates (e.g., bilirubin) into bile canaliculus. Although MRP2 is an essential transporter for the excretion of bilirubin, its role in the clinical course of BA patients is unclear. The present study investigated the relationship between hepatic MRP2 expression and clinical course in BA patients, with particular emphasis in curing jaundice after hepatoportoenterostomy. RESULTS: No significant differences in hepatic MRP2 expression level were observed between BA and controls groups. There was no correlation between MRP2 expression and age at time of surgery in BA and control groups. In BA patients, MRP2 expression level in the jaundice and jaundice-free group did not differ significantly (2.0 × 10(-4 )vs 3.1 × 10(-4), p = 0.094). Although the serum level of total bilirubin just before surgery did not correlate with MRP2 expression level (rs = 0.031, p = 0.914), the serum level of total bilirubin measured at 2 weeks (rs = -0.569, p = 0.034) and 4 weeks after surgery (rs = -0.620, p = 0.018) were significantly correlated with MRP2 expression level. Furthermore, MRP2 expression level was inversely correlated with ratio of change in serum total bilirubin level over 4 weeks (rs = -0.676, p = 0.008), which represents the serum bilirubin level measured at 4 weeks after surgery divided by value just before surgery. There was no correlation between expression level of MRP2 and nuclear receptors, such as retinoid × receptor α, farnesoid × receptor, pregnane × receptor, or constitutive androstane receptor. CONCLUSIONS: Hepatic MRP2 expression level was associated with postoperative clearance of jaundice in BA patients, at least within 1 month after hepatoportoenterostomy. This finding suggests that not only morphological appearance of the liver tissue but also the biological status of hepatocytes is important for BA pathophysiology. BioMed Central 2011-08-03 /pmc/articles/PMC3161838/ /pubmed/21813008 http://dx.doi.org/10.1186/1476-5926-10-6 Text en Copyright ©2011 Terui et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Terui, Keita Saito, Takeshi Hishiki, Tomoro Sato, Yoshiharu Mitsunaga, Tetsuya Yoshida, Hideo Hepatic expression of multidrug resistance protein 2 in biliary atresia |
title | Hepatic expression of multidrug resistance protein 2 in biliary atresia |
title_full | Hepatic expression of multidrug resistance protein 2 in biliary atresia |
title_fullStr | Hepatic expression of multidrug resistance protein 2 in biliary atresia |
title_full_unstemmed | Hepatic expression of multidrug resistance protein 2 in biliary atresia |
title_short | Hepatic expression of multidrug resistance protein 2 in biliary atresia |
title_sort | hepatic expression of multidrug resistance protein 2 in biliary atresia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161838/ https://www.ncbi.nlm.nih.gov/pubmed/21813008 http://dx.doi.org/10.1186/1476-5926-10-6 |
work_keys_str_mv | AT teruikeita hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia AT saitotakeshi hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia AT hishikitomoro hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia AT satoyoshiharu hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia AT mitsunagatetsuya hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia AT yoshidahideo hepaticexpressionofmultidrugresistanceprotein2inbiliaryatresia |